Publication:
Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIIA Registry.

dc.contributor.authorGarcía-Fernández, Amaya
dc.contributor.authorEsteve-Pastor, María Asunción
dc.contributor.authorRoldán-Rabadán, Inmaculada
dc.contributor.authorMuñiz, Javier
dc.contributor.authorRuiz Ortiz, Martín
dc.contributor.authorCequier, Ángel
dc.contributor.authorBertomeu-Martínez, Vicente
dc.contributor.authorBadimón, Lina
dc.contributor.authorOtero, Déborah
dc.contributor.authorAnguita, Manuel
dc.contributor.authorLip, Gregory Y H
dc.contributor.authorMarín, Francisco
dc.contributor.authorFANTASIIA investigators
dc.date.accessioned2023-02-09T09:35:23Z
dc.date.available2023-02-09T09:35:23Z
dc.date.issued2020-06-17
dc.description.abstractAtrial fibrillation (AF) patients with diabetes (DM) have high risk of cardiovascular events. To compare clinical characteristics, adverse outcomes and quality of anticoagulation in AF patients regarding DM status. AF patients from FANTASIIA registry were included. Baseline characteristics and comorbidities were recorded. After 2-years follow-up, the association between adverse events and DM was evaluated. 1956 patients (mean age 73.8 ± 9.5 years, 56% male) were analyzed; 574 (29.3%) had DM. Diabetic patients had also high prevalence of hypertension (90.6% vs 76.1%; p  AF Diabetic patients have higher comorbidities and poorer TTR than nondiabetic patients. Low TTR was associated with adverse events. The risk of cardiovascular outcomes was higher in DM patients, with independent association between DM and mortality risk.
dc.identifier.doi10.1080/07853890.2020.1778176
dc.identifier.essn1365-2060
dc.identifier.pmcPMC7877972
dc.identifier.pmid32500748
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877972/pdf
dc.identifier.unpaywallURLhttps://www.tandfonline.com/doi/pdf/10.1080/07853890.2020.1778176?needAccess=true
dc.identifier.urihttp://hdl.handle.net/10668/15684
dc.issue.number6
dc.journal.titleAnnals of medicine
dc.journal.titleabbreviationAnn Med
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Reina Sofía
dc.page.number300-309
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectAtrial fibrillation
dc.subjectdiabetes mellitus
dc.subjectoral anticoagulation
dc.subjectrisk factors
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAnticoagulants
dc.subject.meshAtrial Fibrillation
dc.subject.meshCase-Control Studies
dc.subject.meshComorbidity
dc.subject.meshDiabetes Mellitus
dc.subject.meshFactor Xa Inhibitors
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshProspective Studies
dc.subject.meshRegistries
dc.titleRelationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIIA Registry.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number52
dspace.entity.typePublication

Files